SynthesisHealth and quality of life outcomes2020
Utility value estimates in cardiovascular disease and the effect of changing elicitation methods: a systematic literature review.
Synthesis in Health and quality of life outcomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- International Systematic Review of Utility Values Associated with Cardiovascular Disease and Reflections on Selecting Evidence for a UK Decision-Analytic Model.Medical decision making : an international journal of the Society for Medical Decision Making · 2024Pooled it
- Cost-effectiveness of early empagliflozin initiation after acute myocardial infarction: a German statutory health insurance perspective.Cost effectiveness and resource allocation : C/E · 2026Article
- A Cardiovascular Care Pathway Supported by Remote Patient Management in Dutch Primary Care: Cost-Effectiveness, Budget Impact, and Workload Analysis.JMIR mHealth and uHealth · 2026Article
- Cost-effectiveness of contingency management for methamphetamine use disorder: A model-based analysis.Addiction (Abingdon, England) · 2026Article
- Cost-effectiveness of opportunistic CT versus clinical methods for sarcopenia screening.Skeletal radiology · 2026Article
- Cost-utility of pneumococcal strategies for adults aged 50 and older in Colombia: a model-based economic evaluation.BMC health services research · 2026Article
- Economic modeling of polygenic risk prediction of coronary artery disease in childhood.NPJ cardiovascular health · 2026Article
- Early Health Technology Assessment (HTA) of Olpasiran and Pelacarsen for Secondary Prevention of Coronary Heart Disease (CHD).ClinicoEconomics and outcomes research : CEOR · 2026Article
- Smoking Cessation Adjuncts Are Cost Effective Prior to Elective Revascularization.Annals of vascular surgery · 2026Article
- Cost-effectiveness of population screening for aortic stenosis.European heart journal. Quality of care & clinical outcomes · 2025Article
- Cost-Effectiveness Analysis of SGLT2 Inhibitors for Cardio-Renal-Metabolic Disease Based on Data from Japanese Studies.Advances in therapy · 2025Article
- Prerequisites for Cost-Effective Home Blood Pressure Telemonitoring: Early Health Economic Analysis.JMIR cardio · 2025Article
- Immediate Versus 5-Year Risk-Guided Initiation of Treatment for Primary Prevention of Cardiovascular Disease for Australians Aged 40 Years: A Health Economic Analysis.PharmacoEconomics · 2025Article
- Health-related quality of life with rivaroxaban plus aspirin vs. aspirin alone in chronic stable cardiovascular disease: Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial.European heart journal open · 2024Article
- A cloud-based medical device for predicting cardiac risk in suspected coronary artery disease: a rapid review and conceptual economic model.Health technology assessment (Winchester, England) · 2024Review
- Canadian Cost-Effectiveness of Coronary Artery Calcium Screening Based on the Multi-Ethnic Study of Atherosclerosis.JACC. Advances · 2024Article
- The Benefits and Harms of Lung Cancer Screening in Individuals With Comorbidities.JTO clinical and research reports · 2024Article
- Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis.PharmacoEconomics · 2024Article
- Cost-utility analysis of a supervised exercise intervention for women with early-stage endometrial cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Economic evaluation of pharmacogenomic-guided antiplatelet treatment in Spanish patients suffering from acute coronary syndrome participating in the U-PGx PREPARE study.Human genomics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveIdentify the most recent utility value estimates for cardiovascular disease (CVD) via systematic literature review (SLR) and explore trends in utility elicitation methods in the last 6 years.
methodsThis SLR was updated on January 25, 2018, and identified studies reporting utilities for myocardial infarction (MI), stroke, angina, peripheral artery disease (PAD), and any-cause revascularization by searching Embase, PubMed, Health Technology Assessment Database, and grey literature.
resultsA total of 375 studies reported CVD utilities (pre-2013 vs post-2013: MI, 38 vs 32; stroke, 86 vs 113; stable angina, 8 vs 9; undefined/unstable angina, 23 vs 8; PAD, 29 vs 13; revascularization, 54 vs 40). Median average utilities for MI, stroke, and revascularization increased over time (pre-2013 vs post-2013: MI, 0.71 vs 0.79; stroke, 0.63 vs 0.64; revascularization, 0.76 vs 0.81); angina and PAD showed a decrease in median values over time (stable angina, 0.83 vs 0.72; undefined/unstable angina, 0.70 vs 0.69; PAD, 0.76 vs 0.71). The proportion of utility estimates from trials increased across health states (pre-2013 vs post-2013: 22.5% vs 37.2%), as did the proportion of trials using the EuroQol Five Dimensions Questionnaire (EQ-5D; pre-2013 vs post-2013: 73.8% vs 91.4%). Use of methods such as the standard gamble, time trade-off, and Health Utilities Index has declined.
conclusionsHealth state utilities for cardiovascular health states have changed in the last 6 years, likely due to changes in the types of studies conducted, the patient populations evaluated, and possibly changing utility elicitation methods. The EQ-5D has been used more frequently.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.